Security Snapshot

PROMIS NEUROSCIENCES INC. - Common Shares, No Par Value per Share (PMN) Institutional Ownership

CUSIP: 74346M406

13F Institutional Holders and Ownership History from Q2 2022 to Q4 2025

13F reference period

n/a

Institutions Reporting

Shares (Excl. Options)

n/a

Price

$0.42

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Shares outstanding
9,550,370
SEC-reported price per share
$0.42
Insider filing price
$0.42
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • PMN - PROMIS NEUROSCIENCES INC. - Common Shares, No Par Value per Share is tracked under CUSIP 74346M406.
  • 13F reference-period holder data is not available.
  • 10 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder data for the Q2 2026 reference period is not available.
  • Available periods remain in the history table; they do not substitute for the headline period.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

74346M406

13F reference period

n/a

13F holders

13D/G owners

10

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
10
Security
PMN
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Shaf QIC LLC 10% $5,096,658 10,534,639 Shaf QIC LLC 29 Jul 2025
Sclar Jeremy M. 17% $3,804,772 9,511,930 Jeremy M. Sclar 30 Sep 2025
ABG Management Ltd. 11% 0% $2,549,570 6,070,405 0% ABG Management Ltd. 29 Jan 2026
JANUS HENDERSON GROUP PLC 14% $542,958 1,292,757 JANUS HENDERSON GROUP PLC 31 Mar 2026
GREAT POINT PARTNERS LLC 10% 0% $400,714 -$2,107,681 954,082 -84% Great Point Partners, LLC 31 Mar 2026
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 10% $376,268 895,877 Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. 11 Mar 2026
WELLINGTON MANAGEMENT GROUP LLP 10% $376,266 895,871 Wellington Management Group LLP 31 Mar 2026
ARMISTICE CAPITAL, LLC 0.93% -77% $211,963 -$1,037,335 504,673 -83% Armistice Capital, LLC 31 Dec 2025
GORDON MICHAEL S 2% -78% $76,285 -$1,975,880 181,632 -96% Michael S. Gordon 31 Mar 2026
SPHERA FUNDS MANAGEMENT LTD. 7.8% +38% $75,893 -$1,235,385 180,698 -94% Sphera Funds Management Ltd. 31 Dec 2025

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
15
Headline period
n/a
Rows shown
1-15 of 15
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$4,247,586 $0.42 0
2025 Q3 9,993,894 $4,247,586 +$501,350 $0.42 23
2025 Q2 8,473,099 $4,101,148 -$540,895 $0.48 19
2025 Q1 9,325,986 $6,489,664 -$305,401 $0.70 17
2024 Q4 9,747,253 $9,238,269 -$516,735 $0.95 18
2024 Q3 10,087,669 $12,611,608 +$8,040,363 $1.25 18
2024 Q2 3,232,221 $4,848,022 -$221,623 $1.50 15
2024 Q1 3,382,907 $6,463,092 +$75,871 $1.91 16
2023 Q4 3,347,909 $3,849,710 +$624,784 $1.15 13
2023 Q3 2,804,768 $5,609,387 +$5,238,947 $1.98 13
2023 Q2 186,447 $723,079 -$4,625 $3.88 12
2023 Q1 187,649 $888,276 -$5,905 $4.73 11
2022 Q4 189,088 $823,550 +$19,204 $4.34 12
2022 Q3 184,593 $1,130,000 +$1,129,000 $6.08 11
2022 Q2 10,000 $1,000 +$1,000 $0.10 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .